C2N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion

C2N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion

C2N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion

ST. LOUIS–(BUSINESS WIRE)–C2N Diagnostics, a leader in advanced brain health diagnostics, which has had a recent series of robust research and funding developments, announces two additions to its executive leadership team. Both these individuals serve in critical roles as the company scales, increases capacity, and deepens its relationship with patients, providers, payers, and commercial partners.

Ozgur Sensoy, who has an established track record of commercialization in the diagnostic and pharmaceutical industries, joins C2N as Senior Vice President of Commercial Operations. In his new role, he will manage C2N’s innovative in vitro diagnostic (IVDx) product pipeline and expand the sales, marketing, and service capabilities of the company to enable broad access in the U.S. and globally for patients and providers. His successful career has involved numerous market development, product launch, and commercialization efforts in multiple specialty disease states. Sensoy spent the last 11 years at Quest Diagnostics where he held multiple leadership positions, managed various mergers-and-acquisitions and integrations, and most recently served as Head of U.S. Specialty Genetics. Prior to Quest, he served in leadership positions at Sanofi and Bayer Pharmaceuticals. Sensoy earned his Master of Business Administration from Yale School of Management and Master of Science and Bachelor of Science Engineering degrees from Bogazici University in Turkey, his native country.

Daniel Connell joins as Head of Strategic Alliances, where he will initially focus on scaling partnerships with Healius Ltd and Grupo Fleury, two recently announced C2N partnerships that are bringing the company’s Precivity™-related blood biomarkers to the forefront of memory and dementia care in Australia and Brazil. He also will expand C2N’s footprint in other international markets and deepen relations with leading biopharmaceutical companies developing next generation therapies for neurodegeneration. Connell joins C2N from AstraZeneca where he supported precision medicine pipeline strategies as Senior Director, Computational Pathology Strategy-Oncology R&D. Prior to AstraZeneca, he led Biogen’s diagnostic strategy in the Intercontinental region, including Alzheimer’s disease launch readiness initiatives in Asia, Oceania, Latin America, and the Middle East. Connell brings substantial precision medicine and personalized healthcare commercial experience to C2N, having worked in global, regional, and field commercial roles at Roche, Novartis, Monogram Biosciences, and Cardinal Health. Connell holds a Bachelor of Science in Biomedical Engineering degree from Washington University in St. Louis and earned an MBA from HEC Paris.

Dr. Joel Braunstein, C2N’s President and CEO, says, “Ozgur and Daniel further complement our dynamic team’s ability to create a vision to bring the best-in-class diagnostic therapeutic monitoring biomarkers in the industry to patients, providers, researchers, and biotherapeutic developers seeking to transform the trajectory of Alzheimer’s disease and brain health, in general. We are thrilled that they see the same vision we see and are dedicating the next phase of their careers to enable us to achieve our goals and ambitions. In just the past few weeks, we’ve announced a significant follow-on investment from GHR Foundation as well as research findings that demonstrate the accuracy of our PrecivityAD® and PrecivityAD2™ blood tests and their future risk-predictive abilities. We look forward to updating the sector about further important commercial developments as we advance our precision medicine focus.”

About C2N Diagnostics, LLC

CN Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. CN strives to provide exceptional laboratory services and products in the field of brain health. CN’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer’s Association. For more information visit www.C2N.com.



Joni Henderson



Adam Shapiro